Bayer has filed a lawsuit against Johnson & Johnson, alleging that the company launched a misleading advertising campaign promoting its prostate cancer treatment. The legal action claims J&J used flawed data to falsely suggest its drug offers superior effectiveness compared to Bayer’s competing therapy. Bayer argues these claims are not supported by reliable clinical evidence and could mislead healthcare providers and patients.
The dispute centers on public statements and marketing materials distributed by J&J, which Bayer contends distort the results of comparative studies. The company maintains that such actions undermine fair competition and compromise informed medical decision-making. This development highlights ongoing tensions between pharmaceutical firms over the accuracy of promotional content in high-stakes therapeutic areas like prostate cancer treatment.